Notably, supplementing plasma samples from AIS patients with a baseline BDNF level of 7.0 ng/mL with rHu-BDNF led to a significant decrease in fibrin clot density (Figure 3b,c). This evidence concerns the gene BDNF and androgen insensitivity syndrome.